JP2008514730A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514730A5 JP2008514730A5 JP2007534859A JP2007534859A JP2008514730A5 JP 2008514730 A5 JP2008514730 A5 JP 2008514730A5 JP 2007534859 A JP2007534859 A JP 2007534859A JP 2007534859 A JP2007534859 A JP 2007534859A JP 2008514730 A5 JP2008514730 A5 JP 2008514730A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- antibody
- seq
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61528404P | 2004-10-01 | 2004-10-01 | |
| PCT/US2005/035477 WO2006039644A2 (en) | 2004-10-01 | 2005-09-30 | Methods of treating cd30 positive lymphomas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008514730A JP2008514730A (ja) | 2008-05-08 |
| JP2008514730A5 true JP2008514730A5 (https=) | 2008-11-20 |
Family
ID=35929979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534859A Pending JP2008514730A (ja) | 2004-10-01 | 2005-09-30 | Ｃｄ３０陽性リンパ腫の処置の方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7790160B2 (https=) |
| EP (1) | EP1802345A2 (https=) |
| JP (1) | JP2008514730A (https=) |
| KR (1) | KR20070083899A (https=) |
| CN (1) | CN101056655A (https=) |
| AU (1) | AU2005292227A1 (https=) |
| BR (1) | BRPI0516727A (https=) |
| CA (1) | CA2582016A1 (https=) |
| IL (1) | IL182260A0 (https=) |
| MX (1) | MX2007003533A (https=) |
| NO (1) | NO20071714L (https=) |
| WO (1) | WO2006039644A2 (https=) |
| ZA (1) | ZA200703154B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162835A0 (en) | 2002-01-09 | 2005-11-20 | Medarex Inc | Human monoclonal antibodies against cd30 |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| WO2006039644A2 (en) | 2004-10-01 | 2006-04-13 | Medarex, Inc. | Methods of treating cd30 positive lymphomas |
| ES2498794T3 (es) | 2005-02-18 | 2014-09-25 | Medarex, L.L.C. | Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo |
| WO2006116246A2 (en) * | 2005-04-25 | 2006-11-02 | Medarex, Inc. | Method of treating cd30 positive lymphomas |
| US20090175886A1 (en) * | 2006-01-17 | 2009-07-09 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
| US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
| EP2155231B1 (en) * | 2007-04-10 | 2012-08-08 | The Johns Hopkins University | Imaging and therapy of virus-associated tumors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| EP3575794A1 (en) | 2012-02-10 | 2019-12-04 | Seattle Genetics, Inc. | Detection and treatment of cd30+ cancers |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| JP6595458B2 (ja) | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| EA201690746A1 (ru) * | 2013-10-25 | 2016-12-30 | Фармасайкликс Элэлси | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии |
| EP3076963A4 (en) * | 2013-12-06 | 2017-09-13 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| CN106716133B (zh) * | 2014-07-11 | 2019-07-30 | 爱科谱迅病理研究公司 | 针对肿瘤坏死因子受体超家族成员8(cd30)蛋白质的srm/mrm测定 |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| MA45862A (fr) * | 2016-08-04 | 2021-05-05 | Millennium Pharm Inc | Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30 |
| CN106854245A (zh) * | 2016-12-28 | 2017-06-16 | 无锡傲锐东源生物科技有限公司 | 抗cd30蛋白单克隆抗体及其用途 |
| CN110678200B (zh) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| ES2965352T3 (es) | 2017-05-30 | 2024-04-12 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3) |
| WO2019148410A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| JP7652918B2 (ja) | 2021-03-01 | 2025-03-27 | ナントバイオ，インコーポレイテッド | 抗ｃｄ３０モノクローナル抗体及びキメラ抗原受容体 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6909191A (en) | 1989-11-20 | 1991-06-13 | Parker, David L. | Improved cd-30 antibodies and fragments thereof |
| US5165923A (en) * | 1989-11-20 | 1992-11-24 | Imperial Cancer Research Technology | Methods and compositions for the treatment of hodgkin's disease |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| DE4200043A1 (de) * | 1991-11-11 | 1993-05-13 | Stein Harald Prof Dr | Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren |
| ATE311895T1 (de) * | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| AU4953693A (en) | 1992-08-25 | 1994-03-15 | Medac Gesellschaft Fur Klinische Spezialpraparate Mbh | Antibody/radioisotope conjugate for tumor diagnosis and/or therapy |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
| ATE186745T1 (de) * | 1995-01-18 | 1999-12-15 | Roche Diagnostics Gmbh | Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern |
| DE19543039C1 (de) | 1995-11-08 | 1996-11-21 | Medac Klinische Spezialpraep | Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30 |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| WO1999040187A1 (de) | 1998-02-06 | 1999-08-12 | Hinrich Abken | Nukleinsäuren zur modulation zellulärer aktivierung |
| DE19937264A1 (de) | 1999-08-06 | 2001-02-15 | Deutsches Krebsforsch | F¶v¶-Antikörper-Konstrukte |
| US6652854B2 (en) | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| AU2001285286A1 (en) | 2000-08-29 | 2002-03-13 | Noveon Ip Holdings Corp. | Hydrogels containing substances |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| CA2463879C (en) * | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| IL162835A0 (en) | 2002-01-09 | 2005-11-20 | Medarex Inc | Human monoclonal antibodies against cd30 |
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
| WO2006039644A2 (en) | 2004-10-01 | 2006-04-13 | Medarex, Inc. | Methods of treating cd30 positive lymphomas |
| ES2498794T3 (es) | 2005-02-18 | 2014-09-25 | Medarex, L.L.C. | Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo |
-
2005
- 2005-09-30 WO PCT/US2005/035477 patent/WO2006039644A2/en not_active Ceased
- 2005-09-30 CN CNA2005800383614A patent/CN101056655A/zh active Pending
- 2005-09-30 US US11/241,154 patent/US7790160B2/en not_active Expired - Fee Related
- 2005-09-30 EP EP05816220A patent/EP1802345A2/en not_active Withdrawn
- 2005-09-30 BR BRPI0516727-2A patent/BRPI0516727A/pt not_active IP Right Cessation
- 2005-09-30 KR KR1020077009968A patent/KR20070083899A/ko not_active Withdrawn
- 2005-09-30 JP JP2007534859A patent/JP2008514730A/ja active Pending
- 2005-09-30 CA CA002582016A patent/CA2582016A1/en not_active Abandoned
- 2005-09-30 ZA ZA200703154A patent/ZA200703154B/xx unknown
- 2005-09-30 AU AU2005292227A patent/AU2005292227A1/en not_active Abandoned
- 2005-09-30 MX MX2007003533A patent/MX2007003533A/es not_active Application Discontinuation
-
2007
- 2007-03-28 IL IL182260A patent/IL182260A0/en unknown
- 2007-03-30 NO NO20071714A patent/NO20071714L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008514730A5 (https=) | ||
| RU2376316C2 (ru) | Человеческие антитела против человеческого 4-1вв (cd137) | |
| JP2009532336A5 (https=) | ||
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| RU2020120539A (ru) | Композиции для ингибирования masp-2-зависимой активации комплемента | |
| JP2024167313A5 (https=) | ||
| JP2010511388A5 (https=) | ||
| JP2019146572A5 (https=) | ||
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| JP2004510752A5 (https=) | ||
| RU2009149294A (ru) | Антиген-связывающие белки, нацеленные на orf0657n s.aureus | |
| RU2007137102A (ru) | Способы лечения боли, вызванной остеоартритом, путем введения антагониста фактора роста нервов и содержащих его композиции | |
| RU2552169C3 (ru) | Высокоаффинные человеческие антитела к pcsk9 | |
| NZ568403A (en) | CD20-specific antibodies and methods of employing same | |
| WO2005044855A3 (en) | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma | |
| JP2013519375A5 (https=) | ||
| AU2016355568A1 (en) | PD1/CTLA4 Binders | |
| RU2008129080A (ru) | Средства и способы лечения опухолевых заболеваний | |
| JP2004517611A5 (https=) | ||
| ATE516819T1 (de) | Verfahren zur behandlung von b-zell-bedingtem krebs | |
| RU2406730C2 (ru) | Гуманизированное моноклональное анти-cd20-антитело | |
| HRP20131085T1 (hr) | Uporaba antagonistiäśkih anti-cd40 monoklonskih antitijela | |
| JP2008541733A5 (https=) | ||
| EP2336183A3 (en) | Antibodies against CCR5 and uses thereof | |
| JP2006512899A5 (https=) |